Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 153 of the 154 references it cites were found in a registry or an index.
Abstract
Decades of research indicate mitochondria from Alzheimer’s disease (AD) patients differ from those of non-AD individuals. Initial studies revealed structural differences, and subsequent studies showed functional deficits. Observations of structure and function changes prompted investigators to consider the consequences, significance, and causes of AD-related mitochondrial dysfunction. Currently, extensive research argues mitochondria may mediate, drive, or contribute to a variety of AD pathologies. The perceived significance of these mitochondrial changes continues to grow, and many currently believe AD mitochondrial dysfunction represents a reasonable therapeutic target. Debate continues over the origin of AD mitochondrial changes. Some argue amyloid-β (Aβ) induces AD mitochondrial dysfunction, a view that does not challenge the amyloid cascade hypothesis and that may in fact help explain that hypothesis. Alternatively, data indicate mitochondrial dysfunction exists independent of Aβ, potentially lies upstream of Aβ deposition, and suggest a primary mitochondrial cascade hypothesis that assumes mitochondrial pathology hierarchically supersedes Aβ pathology. Mitochondria, therefore, appear at least to mediate or possibly even initiate pathologic molecular cascades in AD. This review considers studies and data that inform this area of AD research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondria, too, are damaged by oxidative and nitrosative stress in AD as noted [34].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The presence of Aβ oligomers in mitochondrial membranes is consistent with Aβ-induced mitochondrial dysfunction occurring early in the disease progression timeline [34,53].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Oxidative stress from mitochondrial dysfunction and reactive oxygen species (ROS) accumulation further heightens neuronal vulnerability [6].”
From What Are the Key Biological Pathways Through Which Lifestyle Factors Influence Neurodegeneration? (2025) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Davis, R. E., Miller, S., Herrnstadt, C., Ghosh, S. S., Fahy, E., Shinobu, L. A., Galasko, D., Thal, L. J., Beal, M. F., Howell, N., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4526 · Cited by 341
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“plaques may arguably have AD; a current construct refers to this state as “preclinical AD” [144].”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Premature ageing in mice expressing defective mitochondrial DNA polymerase
Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., Bruder, C. E., Bohlooly-Y, M., Gidlöf, S., Oldfors, A., Wibom, R., et al. (2004) · Nature · doi:10.1038/nature02517 · Cited by 2,734 · cited 1×
“Due to the presence of the mutated mtPOLG transgene, these mice acquire excess somatic mtDNA mutations and mitochondrial dysfunction [65, 66].”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundBloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194 · cited 1×
“In response to this, some now speculate A itself is insufficient to cause the disease, but instead initiates AD by triggering a critical change in tau biology [114, 119, 120].”
Background
Research works printed but not linked: 1
- Parker WD (1990) Sporadic neurologic disease and the electron transport chain: A hyothesis In Proceedings of the 1989 Scientific Meeting of the American Society for Neurological Investigation: New Developments in Neuromuscular Disease, Pascuzzi RM, ed. Indiana University Printing Services, Bloomington, Indiana.
Cited by
Items 101–200 of 856
Zhao, N., Xia, J., & Xu, B. (2021) · Journal of Sport and Health Science · doi:10.1016/j.jshs.2020.08.009 · Cited by 74
“J Sport Health Sc respiratory enzymes, ultrastructural deficits, including the loss of cristae, the development of vacuolar intramedullary lesions, and increased permeability, have been demonstrated in brain tissue in AD patients.5 Consequently, much evidence has been reported showing that excessive reactive oxygen sp…”
BackgroundInfluentialWarning SINEs: Alu elements, evolution of the human brain, and the spectrum of neurological disease
Larsen, P. A., Hunnicutt, K. E., Larsen, R. J., Yoder, A. D., & Saunders, A. M. (2018) · Chromosome Research · doi:10.1007/s10577-018-9573-4 · Cited by 87
“Importantly, these processes would precede macroscopic pathologies such as protein aggregation and neuronal atrophy observed in neurodegenerative diseases (Swerdlow et al. 2010; Larsen et al. 2017; Swerdlow 2017).”
BackgroundDematteis, G., Vydmantaitė, G., Ruffinatti, F. A., Chahin, M., Farruggio, S., Barberis, E., Ferrari, E., Marengo, E., Distasi, C., Morkūnienė, R., et al. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-02911-1 · Cited by 76
de Vries, L. E., Huitinga, I., Kessels, H. W., Swaab, D. F., & Verhaagen, J. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00719-7 · Cited by 72
“To date, many studies have shown mitochondrial dysfunction in the brain of AD patients and impaired energy metabolism is an early and consistent feature in AD [254].”
D’Mello, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115911 · Cited by 85
“Although the precise mechanisms and extents of contribution remain unclear, it is widely accepted that oligomeric Aβ and hyperphosphorylated Tau fibrils along with excitotoxicity, neuroinflammation and abortive cell cycle entry and a variety of other cellular disturbances, including impaired cholinergic signaling [46]…”
BackgroundCarinci, M., Vezzani, B., Patergnani, S., Ludewig, P., Lessmann, K., Magnus, T. U., Casetta, I., Pugliatti, M., Pinton, P., & Giorgi, C. (2021) · Biomedicines · doi:10.3390/biomedicines9020169 · Cited by 90
FMN reduces Amyloid-β toxicity in yeast by regulating redox status and cellular metabolism
Chen, X., Ji, B., Hao, X., Li, X., Eisele, F., Nyström, T., & Petranović, D. (2020) · Nature Communications · doi:10.1038/s41467-020-14525-4 · Cited by 85
The role of synaptic microRNAs in Alzheimer's disease
Kumar, S., & Reddy, P. H. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165937 · Cited by 73
Ding, X.-W., Robinson, M., Li, R., Aldhowayan, H., Geetha, T., & Babu, J. R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105783 · Cited by 88
Galizzi, G., & Carlo, M. D. (2022) · Biology · doi:10.3390/biology11060943 · Cited by 86
“Therefore, based on these results, the mitochon‐ drial cascade hypothesis has been formulated, which is regarded as one of the earliest features in AD [106].”
BackgroundMitostasis, Calcium and Free Radicals in Health, Aging and Neurodegeneration
Godoy, J. A., Ríos, J. A., Picón-Pagès, P., Herrera-Fernández, V., Swaby, B., Crepin, G., Vicente, R., Fernández‐Fernández, J. M., & Muñoz, F. J. (2021) · Biomolecules · doi:10.3390/biom11071012 · Cited by 76
Therapeutic non-invasive brain treatments in Alzheimer’s disease: recent advances and challenges
Wu, C., Yang, L., Feng, S., Zhu, L., Yang, L., Liu, T. C.-Y., & Duan, R. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00216-8 · Cited by 72
“These five enzyme complexes’ reduced expression and activity have been found in the brain of AD patients and animals, suggesting mitochondrial bioenergetic deficit precedes Alzheimer’s pathology [32, 35, 36].”
BackgroundGuha, S. K., Johnson, G. V. W., & Nehrke, K. W. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02084-0 · Cited by 79
Joshi, A. U., Wassenhove, L. D. V., Logas, K. R., Minhas, P. S., Andreasson, K. I., Weinberg, K. I., Chen, C., & Mochly‐Rosen, D. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0839-7 · Cited by 80
Panes-Fernández, J., Godoy, P. A., Silva-Grecchi, T., Celis, M. T., Ramírez-Molina, O., Gavilán, J., Muñoz-Montesino, C., Castro, P. A., Moraga‐Cid, G., Yévenes, G. E., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00709 · Cited by 73
“However, the mechanisms by which AbOs signaling promotes neuronal cell death and mitochondrial dysfunction are unclear (Swerdlow, 2018).”
BackgroundSilva, D. F., Candeias, E., Esteves, A. R., Magalhães, J. D., Ferreira, I. L., Nunes‐Costa, D., Rego, A. C., Empadinhas, N., & Cardoso, S. M. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02004-y · Cited by 79
“The etiology of sporadic AD has been addressed by several different hypotheses such as the mitochondrial cascade hypothesis [12], the amyloid cascade hypothesis [13], the neuroinflammation hypothesis [14], and the infectious theory [15].”
BackgroundAn Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?
Sciaccaluga, M., Megaro, A., Bellomo, G., Ruffolo, G., Romoli, M., Palma, E., & Costa, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115991 · Cited by 70
Advances in polysaccharides of natural source of the anti-Alzheimer's disease effect and mechanism
Zhang, Z., Wang, S., Tan, H., Yang, P., Li, Y., Xu, L., Duan, B., & Liu, Y. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.119961 · Cited by 76
Alzheimer’s disease clinical trial update 2019–2021
Pleen, J., & Townley, R. A. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10790-5 · Cited by 74
Dysfunction of mitochondria: Implications for Alzheimer's disease
Albensi, B. C. (2019) · International Review of Neurobiology · doi:10.1016/bs.irn.2019.03.001 · Cited by 68
Stepanov, Y. V., Golovynska, I., Zhang, R., Golovynskyi, S., Stepanova, L. I., Gorbach, O. I., Dovbynchuk, T., Garmanchuk, L., Ohulchanskyy, T. Y., & Qu, J. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01022-7 · Cited by 73
Ribarič, S. (2023) · Biomedicines · doi:10.3390/biomedicines11020355 · Cited by 66
Liang, J., Wang, C., Zhang, H., Huang, J., Xie, J., & Chen, N. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.755665 · Cited by 75
“The mitochondrial cascade hypothesis is a supplement to the amyloid cascade hypothesis, suggesting the important role of the functional status of mitochondria in the production, modification and accumulation of Aβ and Tau, as well as the formation of oligomers (Swerdlow, 2018).”
BackgroundReassessment of Pioglitazone for Alzheimer’s Disease
Saunders, A. M., Burns, D. K., & Gottschalk, W. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.666958 · Cited by 63
“Swerdlow (2018); Wang et al. (2020) and others (Lin and Beal, 2006; Reddy and Beal, 2008; Gibson et al., 2010; Moreira et al., 2010; Swerdlow et al., 2010, 2014) have thoroughly reviewed the contribution of mitochondrial damage to the pathogenesis of Alzheimer’s, and we note the highlights here.”
BackgroundMitochondrial plasticity and synaptic plasticity crosstalk; in health and Alzheimer's disease
Sayehmiri, F., Motamedi, F., Batool, Z., Naderi, N., Shaerzadeh, F., Zoghi, A., Rezaei, O., Khodagholi, F., & Pourbadie, H. G. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14897 · Cited by 74
“159 Several evidence shows that mitochondrial dysfunction happens earlier than the A β production in AD animal models.”
BackgroundZhao, N., Yan, Q.-W., Xia, J., Zhang, X., Li, B., Yin, L., & Xu, B. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03003-4 · Cited by 67
“Recently, the Aβ deposition is believed to be associated with the mitochondrial dysfunction [3].”
BackgroundSteroids and Alzheimer’s Disease: Changes Associated with Pathology and Therapeutic Potential
Akwa, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134812 · Cited by 62
“Alternatively, mitochondrial dysfunction can generate Aβ accumulation or be independent of Aβ (for review [101]).”
BackgroundPositive Feedback Loops in Alzheimer’s Disease: The Alzheimer’s Feedback Hypothesis
Doig, A. J. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180583 · Cited by 62
Fišar, Z., Hansíková, H., Křížová, J., Jirák, R., Kitzlerová, E., Zvěřová, M., Hroudová, J., Wenchich, L., Zeman, J., & Raboch, J. (2019) · Mitochondrion · doi:10.1016/j.mito.2019.07.013 · Cited by 75
Xu, Y., Xu, L., Han, M., Liu, X., Li, F., Zhou, X., Wang, Y., & Bi, J. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.09.094 · Cited by 67
Guha, S. K., Fischer, S., Johnson, G. V. W., & Nehrke, K. W. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00410-7 · Cited by 62
“Mitochondrial dysfunction is a characteristic of many neurodegenerative diseases including AD [24, 25], and over expression of human full length tau or mutant human tau contributes to mitochondrial dysfunction in AD animal models [26, 27].”
BackgroundShin, S. J., Nam, Y., Park, Y. H., Kim, M., Lee, E., Jeon, S. G., Bae, B.-S., Seo, J., Shim, S., Kim, J.-S., et al. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.12.454 · Cited by 62
Mitochondrial disorders leading to Alzheimer’s disease—perspectives of diagnosis and treatment
Pszczołowska, M., Walczak, K., Miśków, W., Mroziak, M., Chojdak-Łukasiewicz, J., & Leszek, J. (2024) · GeroScience · doi:10.1007/s11357-024-01118-y · Cited by 68
“In Du et al.’s study, the bound component of a transition pore–cyclophilin D also leads to oxidative stress and apoptosis and, as a study on AβPP mice showed, impacts on preservation of cognitive function [29].”
BackgroundCieślik, M., Czapski, G. A., Wójtowicz, S., Wieczorek, I., Wencel, P. L., Strosznajder, R. P., Jaber, V., Lukiw, W. J., & Strosznajder, J. B. (2020) · Molecular Neurobiology · doi:10.1007/s12035-019-01819-y · Cited by 61
The Dawn of Mitophagy: What Do We Know by Now?
Belousov, D. M., Вячеславовна, М. Е., Somasundaram, S. G., Kirkland, C. E., & Aliev, G. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200522202319 · Cited by 62
“During PINK1/ Parkin-dependent mitophagy, Optineurin/NDP52-dependent ULK1 recruitment to depolarized mitochondria occurs, which is accompanied by the transport of ATG9A-vesicles to ULK1 and subsequent PI3P-dependent ATG9A dissociation [6, 260].”
BackgroundAbuelezz, N. Z., Nasr, F. E., AbdulKader, M. A., Bassiouny, A. R., & Zaky, A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.743573 · Cited by 59
“Interestingly, mitochondrial alterations have been consistently observed before the clinical onset of AD (Swerdlow, 2018).”
BackgroundATP synthase and Alzheimer’s disease: putting a spin on the mitochondrial hypothesis
Ebanks, B., Ingram, T. L., & Chakrabarti, L. (2020) · Aging · doi:10.18632/aging.103867 · Cited by 62
The molecular mechanism, targets, and novel molecules in the treatment of Alzheimer’s disease
Verma, A., Waiker, D. K., Bhardwaj, B., Saraf, P., & Shrivastava, S. K. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105562 · Cited by 60
Yin, Z., Gao, D., Du, K., Chen, H., Liu, Y., Wang, Y., & Gao, X. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/2524832 · Cited by 62
“…and inhibit the production of ROS from ETC. Mounting evidence has shown that ROS accelerate the generation and accumulation of misfolded A β by upregulating the expression level of amyloid precursor protein in neurons as well as its active enzyme, β -site APP-cleaving enzyme 1 [63, 64].”
Mitochondrial dysfunction in Alzheimer’s disease: a key frontier for future targeted therapies
Wang, S., Liao, Z., Zhang, Q., Han, X., Liu, C., & Wang, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1484373 · Cited by 84
“Recent studies have identi fi ed several proteins closely related to mitochondrial dynamics, including Drp1, mitofusins 1/2 (Mfn1/2), mitochondrial fi ssion protein 1 (Fis1), and mitochondrial fi ssion factor (Mff) (37, 38).”
Shin, S. J., Jeon, S. G., Kim, J.-I., Jeong, Y.-O., Kim, S., Park, Y. H., Lee, S.-K., Park, H. H., Hong, S. B., Oh, S., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123030 · Cited by 58
“Mitochondrial dysfunction is associated with Aβ accumulation [9].”
BackgroundInfluentialTaylor, M. K., Swerdlow, R. H., & Sullivan, D. K. (2019) · Nutrients · doi:10.3390/nu11081910 · Cited by 65
“Regardless of whether bioenergetic deficit is a culprit or a consequence in AD etiology, therapies targeting this dysfunction may have a role in modifying disease trajectory in patients [103].”
BackgroundSelf-citationChen, J., Bassot, A., Giuliani, F., & Simmen, T. (2021) · Cells · doi:10.3390/cells10071789 · Cited by 63
Yao, P. J., Eren, E., Goetzl, E. J., & Kapogiannis, D. (2021) · Biomedicines · doi:10.3390/biomedicines9111587 · Cited by 68
“Aβ and ROS synergistically damage synapses, activate microglia and neuroinflammation, and impair functions of the cerebral microvasculature and the blood brain barrier [1,30,33].”
BackgroundResultInfluentialAmyloid beta-mediated KIF5A deficiency disrupts anterograde axonal mitochondrial movement
Wang, Q., Tian, J., Chen, H., Du, H., & Guo, L. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.03.021 · Cited by 56
Metabolic perspective of astrocyte dysfunction in Alzheimer's disease and type 2 diabetes brains
Shen, Z., Li, Z., Yu, M., Tan, K.-L., & Chen, S. X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114206 · Cited by 58
The basic machineries for mitochondrial protein quality control
Vazquez‐Calvo, C., Suhm, T., Büttner, S., & Ott, M. (2019) · Mitochondrion · doi:10.1016/j.mito.2019.10.003 · Cited by 59
Park, Y. H., Shin, S. J., Kim, H. S., Hong, S. B., Kim, S., Nam, Y., Kim, J.-J., Lim, K., Kim, J.-S., Kim, J.-I., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113879 · Cited by 54
“It was shown that Aβ-treated HT22 cells exhibit a significant decrease in basal respiration, resulting from mitochondrial proton seepage and ATP demand caused by Aβ treatment.”
BackgroundInfluentialEffects of Urolithin A on Mitochondrial Parameters in a Cellular Model of Early Alzheimer Disease
Esselun, C., Theyssen, E., & Eckert, G. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158333 · Cited by 63
“Mitochondrial dysfunction plays a prominent role in the aging process and is part of the pathogenesis of neurodegenerative diseases including AD [3,19,46,47].”
BackgroundStressed mitochondria: A target to intrude alzheimer’s disease
Sharma, V., Singh, T. G., & Mehta, V. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.04.004 · Cited by 55
Mitochondrial ATP Synthase is a Target of Oxidative Stress in Neurodegenerative Diseases
Ebanks, B., & Chakrabarti, L. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.854321 · Cited by 60
“An updated consideration of this hypothesis considers how mitochondrial dysfunction can lead to oxidative stress, independent of intramitochondrial Aβ (Swerdlow, 2018).”
BackgroundInfluentialThe role of mitochondrial dysfunction in Alzheimer's disease: A potential pathway to treatment
Reiss, A. B., Ahmed, S., Dayaramani, C., Glass, A. D., Gomolin, I. H., Pinkhasov, A., Stecker, M. M., Wısnıewskı, T., & Leon, J. D. (2022) · Experimental Gerontology · doi:10.1016/j.exger.2022.111828 · Cited by 58
Neuroprotective Mechanisms of Puerarin in Central Nervous System Diseases: Update
Yu, C.-C., Du, Y.-J., Li, J., Li, Y., Wang, L., Kong, L.-H., & Zhang, Y. (2022) · Aging and Disease · doi:10.14336/ad.2021.1205 · Cited by 57
Mitochondrial links between brain aging and Alzheimer’s disease
Wilkins, H., & Swerdlow, R. H. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00261-2 · Cited by 56
“The COX activity or related function is lower in AD brain tissues, platelets, and fibroblasts than in age-matched groups [42, 50].”
BackgroundSelf-citationAccumulation of APP-CTF induces mitophagy dysfunction in the iNSCs model of Alzheimer’s disease
Lee, S.-E., Kwon, D., Shin, N., Kong, D., Kim, N. G., Kim, H.-Y., Kim, M.-J., Choi, S. W., & Kang, K.-S. (2022) · Cell Death Discovery · doi:10.1038/s41420-021-00796-3 · Cited by 53
“Consistent with the observation that damaged energy metabolism continues prior to the clinical onset of AD, abnormal mitochondria has been established as an early sign of proceeding AD and contributing to the progression of the disease [10].”
BackgroundAging-Dependent Mitophagy Dysfunction in Alzheimer’s Disease
Song, M., Zhao, X., & Song, F. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02248-y · Cited by 60
Multi-Target-Directed Ligands as an Effective Strategy for the Treatment of Alzheimer’s Disease
Kumar, R., Kumar, V., Kumar, B., Thakur, A., & Dwivedi, A. R. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210512005508 · Cited by 57
The Potentials of Methylene Blue as an Anti-Aging Drug
Xue, H., Thaivalappil, A., & Cao, K. (2021) · Cells · doi:10.3390/cells10123379 · Cited by 68
“Conversely, the damaged mitochondrial function can induce aberrant A β production and promote abnormal phosphorylation of tau [50].”
BackgroundExtracellular vesicles: translational research and applications in neurology
Manolopoulos, A., Yao, P. J., & Kapogiannis, D. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01080-z · Cited by 63
“The mitochondrial cargo of NDEVs might reflect the structural and functional mitochondrial abnormalities that are seen in Alzheimer disease 84 .”
Exploring the dual character of metformin in Alzheimer's disease
Ning, P., Luo, A., Mu, X. L., Xu, Y., & Li, T. X. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108966 · Cited by 53
Sheng, N., Zhang, Z., Zheng, H., Ma, C., Li, M., Wang, Z., Wang, L., Jiang, J., & Zhang, J. (2023) · Advanced Science · doi:10.1002/advs.202303584 · Cited by 65
Pegoraro, C., Domingo-Ortí, I., Conejos‐Sánchez, I., & Vicent, M. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115195 · Cited by 59
Artemisinin inhibits neuronal ferroptosis in Alzheimer’s disease models by targeting KEAP1
Deng, P.-X., Silva, M., Yang, N., Wang, Q., Meng, X., Ye, K., Gao, H., & Zheng, W. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01378-6 · Cited by 63
“Artemisinin alleviates A β 1 − 42 ‑ induced ferroptosis via the KEAP1-Nrf2 pathway Beta-amyloid (A β ) accumulation, a neuropathological hallmark of AD, leads to mitochondrial dysfunction and ferroptosis [40, 41].”
Targeting Alzheimer’s Disease: The Critical Crosstalk between the Liver and Brain
Huang, Z., Lin, H. W. (., Zhang, Q., & Zong, X. (2022) · Nutrients · doi:10.3390/nu14204298 · Cited by 50
Neuroprotection in Glaucoma: NAD+/NADH Redox State as a Potential Biomarker and Therapeutic Target
Petriti, B., Williams, P. A., Lascaratos, G., Chau, K., & Garway‐Heath, D. F. (2021) · Cells · doi:10.3390/cells10061402 · Cited by 55
“Mitochondrial dysfunction is associated with numerous age–related neurodegenerative diseases including Parkinson’s disease (PD) and Alzheimer’s disease (AD) and it is likely that these diseases may share common pathophysiological mechanisms [4,5].”
BackgroundHou, Y., Zhao, W., Yu, H., Zhang, F., Zhang, H., & Zhou, Y. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154056 · Cited by 52
Hajjo, R., Sabbah, D. A., Abusara, O. H., & Bawab, A. Q. A. (2022) · Diagnostics · doi:10.3390/diagnostics12122975 · Cited by 62
CoQ10 and Mitochondrial Dysfunction in Alzheimer’s Disease
Fišar, Z., & Hroudová, J. (2024) · Antioxidants · doi:10.3390/antiox13020191 · Cited by 68
“According to the mitochondrial cascade hypothesis, AD neuropathology arises secondary to mitochondrial dysfunction when the age-associated decline in mitochondrial function reaches a point where compensatory mechanisms are no longer effective [8,56,57].”
BackgroundHuang, Z., Hamblin, M. R., & Zhang, Q. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01484-x · Cited by 56
“Emerging research suggests that mitochondrial dysfunction, which may either derive from Aβ deposition or occur independently of Aβ pathology, potentially presents a brain “energy crisis” and contributes to the onset of AD [80, 81].”
Background(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.03.018 · Cited by 50
Geng, Z., Guan, S., Wang, S., Yu, Z., Liu, T., Du, S., & Zhu, C. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14344 · Cited by 52
Molecular Mechanism of Vitamin K2 Protection against Amyloid-β-Induced Cytotoxicity
Huang, S.-H., Fang, S.-T., & Chen, Y.-C. (2021) · Biomolecules · doi:10.3390/biom11030423 · Cited by 55
“Aβ-induced cytotoxicity is linked to oxidative stress [11,12], perturbation of intracellular calcium homeostasis [13], overproduction of tumor necrosis factor-α (TNF-α) [14], mitochondrial dysfunction [11,12,15] and apoptosis [10,16,17].”
BackgroundYeung, J. H. Y., Walby, J. L., Palpagama, T. H., Turner, C. P., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2021) · Brain Pathology · doi:10.1111/bpa.13005 · Cited by 52
The Legend of ATP: From Origin of Life to Precision Medicine
Chu, X., Xu, Y., Tong, X., Wang, G., & Zhang, H. (2022) · Metabolites · doi:10.3390/metabo12050461 · Cited by 51
Jasbi, P., Shi, X., Chu, P. S., Elliott, N. M., Hudson, H., Jones, D. C., Serrano, G. E., Chow, B., Beach, T. G., Liu, L., et al. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00290 · Cited by 50
Stanciu, G. D., Rusu, R. N., Bild, V., Filipiuc, L. E., Tamba, B.-I., & Ababei, D. C. (2021) · Biomedicines · doi:10.3390/biomedicines9050576 · Cited by 47
“They provide a basis for therapeutic approaches to restore AD-related metabolic, mitochondrial and endo-lysosomal dysfunctions; changes that occur early in the progression of the disease in relation to tau and Aβ deposition, which means that they are viable factors of AD development [34,35].”
BackgroundSong, H., Chen, M., Chen, C., Cui, J., Johnson, C. E., Cheng, J., Wang, X., Swerdlow, R. H., DePalma, R. G., Xia, W., et al. (2018) · Journal of Neurotrauma · doi:10.1089/neu.2018.6114 · Cited by 48
“neuronal cell function and contribute to the development or progression of neurodegeneration.(10,38) Defects in mitochondrial bioenergetics and associated metabolic function are known to link with”
BackgroundSelf-citationde Dios, C., Bartolessis, I., Roca-Agujetas, V., Barbero-Camps, E., Mari, M., Morales, A., & Colell, A. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101283 · Cited by 47
“Aβ toxicity linked to mitochondrial dysfunction has been described to mediate or even initiate key pathologic molecular cascades in AD [52].”
BackgroundMishra, A., Wang, Y., Yin, F., Vitali, F., Rodgers, K. E., Soto, M., Mosconi, L., Wang, T., & Brinton, R. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101542 · Cited by 60
“It is clear, however, that hypometabolism and neuroinflammation are well-documented contributors to AD (Akhter et al., 2017; Gibson and Shi, 2010; Ransohoff, 2016; Swerdlow, 2018).”
Zhang, Y., Liu, S., Cao, D., Zhao, M., Lu, H., & Wang, P. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119285 · Cited by 51
Cell type-specific potential pathogenic genes and functional pathways in Alzheimer’s Disease
Wang, X.-L., & Li, L. (2021) · BMC Neurology · doi:10.1186/s12883-021-02407-1 · Cited by 46
Mechanisms of Mitochondrial Malfunction in Alzheimer’s Disease: New Therapeutic Hope
Nabi, S. U., Khan, A., Siddiqui, E. M., Rehman, M. U., Alshahrani, S., Arafah, A. M., Mehan, S., Alsaffar, R. M., Alexiou, A. T., & Shen, B. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/4759963 · Cited by 55
“The mitochondria then take in the calcium, which is one of the cell’s calcium regulators [83].”
Chen, H., Li, N., Liu, N., Zhu, H., Ma, C., Ye, Y., Shi, X., Luo, G., Dong, X., Tan, T., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01714-w · Cited by 55
“Mitochondrial dysfunction is a significant pathological phenomenon in AD [21].”
Role of mtDNA disturbances in the pathogenesis of Alzheimer’s and Parkinson’s disease
Antonyová, V., Kejík, Z., Brogyányi, T., Kaplánek, R., Pajková, M., Talianová, V., Hromádka, R., Masařík, M., Sýkora, D., Mikšátková, L., et al. (2020) · DNA Repair · doi:10.1016/j.dnarep.2020.102871 · Cited by 45
Brunetti, D., Bottani, E., Segala, A., Marchet, S., Rossi, F., Orlando, F., Malavolta, M., Carruba, M. O., Lamperti, C., Provinciali, M., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01171 · Cited by 46
“Extensive research purports that mitochondrial derangements contribute to AD pathogenesis or possibly even initiate pathologic molecular cascades upstream of amyloid-b (Ab) deposition in AD (Swerdlow, 2018).”
BackgroundInfluentialVolloch, V., & Rits, S. (2018) · Medical Sciences · doi:10.3390/medsci6020045 · Cited by 44
“[13]), Presenilin Hypothesis (PH), and βAPP Matrix Approach (AMA) (both reviewed in ref.”
BackgroundEmerging nanotechnology for Alzheimer's disease: From detection to treatment
Song, N., Sun, S., Chen, K., Wang, Y., Wang, H., Meng, J., Guo, M., Zhang, X.-D., & Zhang, R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.004 · Cited by 44
Molecular Genetics of Early- and Late-Onset Alzheimer’s Disease
Uddin, M. S., Hasana, S., Hossain, M. F., Islam, M. S., Behl, T., Perveen, A., Hafeez, A., & Ashraf, G. M. (2020) · Current Gene Therapy · doi:10.2174/1566523220666201123112822 · Cited by 64
Zhang, Y., Qian, L., Liu, Y., Liu, Y., Yu, W., & Zhao, Y. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.665788 · Cited by 48
“As the main components of nucleic acids, nucleobases, nucleosides, nucleotides and related phosphorylated metabolites have many important roles as intermediates in biosynthetic pathways in biological systems (Lane and Fan, 2015; Swerdlow, 2018; Muguruma et al., 2020).”
BackgroundLi, R., Wang, L., Duan, H., Zhang, Q., Guo, X., Wu, C., & Peng, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.937289 · Cited by 60
“development of neurodegenerative diseases (Swerdlow, 2018).”
BackgroundAtlante, A., Valenti, D., Latina, V., & Amadoro, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147722 · Cited by 45
Mahley, R. W. (2023) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2023.102684 · Cited by 43
Zhao, W., Hou, Y., Song, X., Wang, L., Zhang, F., Zhang, H., Yu, H., & Zhou, Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.713819 · Cited by 49
“Many studies have indicated that abnormal mitochondrial bioenergetics is an important pathological feature of several neurodegenerative diseases (Swerdlow, 2018; Fišar et al., 2019).”
BackgroundDieter, F., Esselun, C., & Eckert, G. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169186 · Cited by 44
“Advancing age leads to mitochondrial dysfunction and also plays a major role in the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease (AD) [7,32,33].”
BackgroundWang, S.-S., Li, X., Liu, P., Li, J., & Liu, L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.972982 · Cited by 49
“Many previous studies (Zhao and Gong, 2015; Swerdlow, 2018; Nguyen et al., 2020) suggest that mitochondrial dysfunction, insulin resistance and cerebral hypoperfusion may mediate, drive or even trigger pathological molecular cascades in AD, ultimately promoting Aβ accumulation, tau hyperphosphorylation, synaptic degen…”
BackgroundDendrimers in Alzheimer’s Disease: Recent Approaches in Multi-Targeting Strategies
Arbez‐Gindre, C., Steele, B. R., & Micha‐Screttas, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030898 · Cited by 49
“Conversely, certain molecular mechanisms seem to support a secondary mitochondrial hypothesis in which ROS-induced mitochondrial dysfunction is influenced by upstream pathologies including Aβ [41,47].”
BackgroundMichalska, P., Mayo, P., Fernández‐Mendívil, C., Tenti, G., Duarte, P., Buendía, I., Ramos, M. T., López, M. G., Menéndez, J. C., & Leon, R. M. (2020) · Antioxidants · doi:10.3390/antiox9080650 · Cited by 45
Potential of Sorghum Polyphenols to Prevent and Treat Alzheimer’s Disease: A Review Article
Rezaee, N., Fernando, W. M. A. D. B., Hone, E., Sohrabi, H. R., Johnson, S. K., Gunzburg, S. T., & Martins, R. N. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.729949 · Cited by 48
The expression pattern of GDF15 in human brain changes during aging and in Alzheimer’s disease
Chiariello, A., Valente, S., Pasquinelli, G., Baracca, A., Sgarbi, G., Solaini, G., Medici, V., Fantini, V., Poloni, T. E., Tognocchi, M., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1058665 · Cited by 44
“Accordingly, a large amount of evidence has shown that mitochondria impairment precedes the clinical onset of AD, indicating the critical role of these organelles in the development of this neuropathology (Swerdlow, 2018; Wang et al., 2020).”
BackgroundVijayan, M., Alvir, R. V., Alvir, R. V., Bunquin, L. E., Pradeepkiran, J. A., & Reddy, P. H. (2022) · Aging Cell · doi:10.1111/acel.13663 · Cited by 40
“There is extensive literature supporting the role of mitochondrial dysfunction and oxidative damage in the pathogenesis of AD (Gowda et al., 2021; Han, Jeong, Sheshadri, & Cai, 2020; Han, Jeong, Sheshadri, Su, & Cai, 2020; Lin & Beal, 2006; Reddy & Beal, 2008; Swerdlow, 2018).”
Background
Metadata
- Authors
- Swerdlow, R. H.
- Affiliations
- University of Kansas (US)
- Corresponding author
- Swerdlow, Russell H.
- ORCID
- Swerdlow, Russell H.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-10-07
- Volume
- 62
- Issue
- 3
- Pages
- 1403-1416
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5869994
- OpenAlex
- W2764071986
- Cited by
- 850
- References
- 154
- Citations by year
- 2026: 126 · 2025: 106 · 2024: 97 · 2023: 110 · 2022: 122 · 2021: 114 · 2020: 106 · 2019: 49 · 2018: 18 · 2017: 1
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG035982)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, mitochondrial dysfunction
- MeSH terms
- Alzheimer Disease, Animals, Humans, Mitochondria
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.